Daniel P. Petrylak

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626885

Top 100%

0DataRank

Top 100%0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Papers

Driven by 24 papers — median percentile 0. Top paper: “Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial”.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00004-8

N/A

5.8DataRank · unranked

418 citations

Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano +21 more

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02887

N/A

4.4DataRank · unranked

181 citations

Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar +20 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.11.012

N/A

3.4DataRank · unranked

116 citations

Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky +15 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0.559DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

ESMO Open(2024)10.1016/j.esmoop.2024.103972

N/A

0.515DataRank · unranked

30 citations

M.D. Galsky, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Y. Loriot +19 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661

N/A

0.510DataRank · unranked

29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4505

N/A

0.470DataRank · unranked

22 citations

Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes +14 more

Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0306

N/A

0.470DataRank · unranked

22 citations

Shijia Zhu, Vijayakumar Jawalagatti, Marc Carceles-Cordon, Adam Ertel, Saioa Garcia‐Longarte +20 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0.457DataRank · unranked

8 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network Survey of Oncology Research Professionals.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11049

N/A

0.385DataRank · unranked

12 citations

Connie M. Szczepanek, Daniel P. Petrylak, Dana B. Sparks, Catherine M. Tangen, Primo N. Lara +3 more

Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4506

N/A

0.312DataRank · unranked

7 citations

Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie +11 more

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

European Urology(2026)10.1016/j.eururo.2025.12.021

N/A

0.241DataRank · unranked

4 citations

Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers +11 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0.208DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps581

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.161

N/A

0DataRank · unranked

0 citations

Junghee J. Shin, Jennefer Par‐Young, Joseph M. Vinetz, Daniel P. Petrylak, Insoo Kang +2 more

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps591

N/A

0DataRank · unranked

1 citations

Melissa Plets, Michael A. Liss, Joshua J. Meeks, Daniel P. Petrylak, Suzanne Cole +9 more

Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.431

N/A

0DataRank · unranked

10 citations

Matthew I. Milowsky, Noah M. Hahn, David J. Kwiatkowski, Alicia K. Morgans, Nancy B. Davis +10 more

Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626876

N/A

0DataRank · unranked

0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626885

Top 100%

0DataRank

Top 100%0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.c.6666732.v2

N/A

0DataRank · unranked

0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4608

N/A

0DataRank · unranked

0 citations

Melissa Plets, Primo N. Lara, Catherine M. Tangen, Rick Bangs, Seth P. Lerner +4 more

Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer

British Journal of Urology(2020)10.1111/bju.15227

N/A

0DataRank · unranked

13 citations

Fatima Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen +22 more

Daniel P. Petrylak

Indexed papers

Top data-sharing exemplar

Papers